

81 Divekar AA, Khanna D, Abtin F *et al.* Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. *Clin Immunol* 2011;141: 293–303.

82 Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. *J Immunol* 2005;175: 3463–8.

83 Denton CP, Merkel PA, Furst DE *et al.* Recombinant human anti-transforming growth factor β 1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. *Arthritis Rheum* 2007;56:323–33.

84 Corren J, Lemanske RF, Hanania NA *et al.* Lebrikizumab treatment in adults with asthma. *N Engl J Med* 2011;365: 1088–98.

Clinical vignette

Rheumatology 2012;51:1549

doi:10.1093/rheumatology/kes159

Advance Access publication 4 July 2012

Giant cell arteritis followed by idiopathic retroperitoneal fibrosis in the same patient—an unexpected positron emission tomography finding

A 78-year-old male patient was diagnosed with GCA, confirmed by positive histology of the temporal artery. Treatment with prednisone 1 mg/kg of body weight was initiated, tapered and stopped after 2 years. Two years later, with unremarkable regular controls, the patient presented with lumbar pain, elevated ESR (41 mm/h) and CRP (27 mg/l). PET-CT scan (Fig. 1A) was performed, showing moderately elevated fluoro-deoxy-glucose (FDG) uptake in both femoral arteries and a retroperitoneal metabolically active mass partially obstructing the left urether. MRI scans of the abdomen (Fig. 1B) were consistent with the diagnosis of idiopathic retroperitoneal fibrosis (IRF) with left-sided grade I hydronephrosis. IgG₄ was initially elevated to 2.00 g/l (normal range 0.08–1.4 g/l) subsiding to 0.62 g/l under treatment with prednisone (1 mg/kg body weight). With 5 mg of prednisone per day, both diseases have remained inactive for the past 6 months.

This case describes a patient suffering from both GCA and IRF, an IgG₄-related sclerosing disease often associated with elevation of the IgG₄ subclass. IRF has not yet been described in patients with GCA. However, similarities in histopathology with inflammation in the medial and adventitial layers of the aorta suggest common yet unproven pathogenetic mechanisms for IRF and GCA.

Disclosure statement: The authors have declared no conflicts of interest.

Peter A. R. Tölle¹, Frederike Kesten² and Thomas Daikeler³


¹Department of Rheumatology, Bethesda Hospital,

²Outpatient Department of Medicine and ³Department of Rheumatology, University Hospital of Basle, Basle, Switzerland.

Correspondence to: Peter Tölle, Department of Rheumatology, Bethesda Hospital, Gellertstrasse 144, Postfach, 4020 Basle, Switzerland.

E-mail: petertoelle@web.de; peter.toelle@bethesda.ch

Fig. 1 Whole-body PET scan and MRI of the abdomen in a patient with GCA and IRF.



(A) The PET scan shows focal FDG enhancement periaortal at the level of the aortic bifurcation (difficult to discriminate from the adjacent urether) and retention of nuclide activity due to hydronephrosis. (B) The transverse MRI of the abdomen with gadolinium-enhanced T1-weighted, fat-saturated fast spin echo shows marked periaortic uptake of contrast material just proximal to the aortic bifurcation.